| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/05/2006 | US20060003944 Bacterial efflux pump inhibitors and methods of treating bacterial infections |
| 01/05/2006 | US20060003943 Protease enzyme inhibitors |
| 01/05/2006 | US20060003942 Combinations for HCV treatment |
| 01/05/2006 | US20060003941 Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity |
| 01/05/2006 | US20060003940 T-cell death-inducing epitopes |
| 01/05/2006 | US20060003939 Stimulating or accelerating apoptosis by contacting cell with an (Inhibitor of Apoptosis Protein) IAPi-derived peptide having a Trp-box consensus sequence and an RHG amino acid consensus sequence; antitumor, anticarcinogenic and antiinflammatory agents; induces self-ubiquitination; drug screening |
| 01/05/2006 | US20060003938 Novel pyrrhocoricin-derived peptides and methods of use thereof |
| 01/05/2006 | US20060003937 Urocortin-III and uses thereof |
| 01/05/2006 | US20060003935 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003934 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 01/05/2006 | US20060003933 Compositions and methods for treatment of neovascular diseases |
| 01/05/2006 | US20060003932 Method for promoting neovascularization |
| 01/05/2006 | US20060003931 Crystal structure of the hepatocyte growth factor and methods of use |
| 01/05/2006 | US20060003930 CD39/ecto-adpase for treatment of thrombotic and ischemic disorders |
| 01/05/2006 | US20060003929 variants or fragments of the Drosophilia sog proteins, used in the therapy of alopecia, cancers or neurodegenerative disorders |
| 01/05/2006 | US20060003928 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 01/05/2006 | US20060003927 Modulation of immune function |
| 01/05/2006 | US20060003926 Anticancer, antitumor agents; mixture of metal, drug, peptide and carriers |
| 01/05/2006 | US20060003925 Using adenosine monophosphate moderator and phosphodiesterase inhibitor |
| 01/05/2006 | US20060003924 Sulfation-independent L-selectin or E-selectin ligand (HCELL) and therapeutics thereof |
| 01/05/2006 | US20060003923 Stability, reduced toxicity; covalently linked imidazole functionality |
| 01/05/2006 | US20060003922 Spinner preparation machine and cavity resonator |
| 01/05/2006 | US20060003921 Pharmaceutical preparation comprising vWF propeptide |
| 01/05/2006 | US20060003920 LAT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003919 Cosmetic/dermatological applications of LIF |
| 01/05/2006 | US20060003918 Prolonged delivery of peptides |
| 01/05/2006 | US20060003917 Bisphosphonate coated implant device and method therefor |
| 01/05/2006 | US20060003916 Parathyroid hormone-related protein (PTHrP) specific antibodies for targeted treatment of kidney, liver and/or lung specic cell proliferative disorders; Antitumor agents |
| 01/05/2006 | US20060003915 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/05/2006 | US20060003450 introducing a selectable marker that is under the control of a promoter of a gene that is differentially expressed in neural progenitor, culturing in vitro to induce differentiation into neural progenitor cells and selecting for the marker |
| 01/05/2006 | US20060003419 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003418 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003417 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 01/05/2006 | US20060003409 Novel molecules of the card-related protein family and uses thereof |
| 01/05/2006 | US20060003407 Methods for preparing highly active april ligand polypeptides |
| 01/05/2006 | US20060003380 Human tumor necrosis factor receptor TR-17 |
| 01/05/2006 | US20060003379 Smad6 and uses thereof |
| 01/05/2006 | US20060003378 Expressed by keratinocytes, wound-healing and chondrosarcoma tissue; nucleic acids comprising polynucleotide of given sequence; use in diagnostics and therapeutics |
| 01/05/2006 | US20060003377 Therapeutic and diagnostic proteins comprising a SOCS box |
| 01/05/2006 | US20060003375 Novel polypeptide - human retinoic acid-responsive protein 53.57 and a polynucleotide encoding the same |
| 01/05/2006 | US20060003364 GLUT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003317 Drug discovery method |
| 01/05/2006 | US20060003073 adsorption of whey proteins onto ion exchange resins, then desorbing by flowing bufferd solutions and collecting the desorbed nondenatured whey proteins, having low turbidity in solution across a wide range of pH values including their isoelectric points |
| 01/05/2006 | US20060003009 Slow release protein polymers |
| 01/05/2006 | US20060003008 Polymeric devices for controlled release of active agents |
| 01/05/2006 | US20060002996 Stable spray-dried protein formulations |
| 01/05/2006 | US20060002993 Genetic engineered protein; transgenic animal, used to elicit a humoral or cellular immune response |
| 01/05/2006 | US20060002991 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 01/05/2006 | US20060002983 Muscle building preparation |
| 01/05/2006 | US20060002978 Biodegradable scaffolds and uses thereof |
| 01/05/2006 | US20060002975 Method and apparatus for reducing tissue damage after ischemic injury |
| 01/05/2006 | US20060002972 Reconstruction of urological structures with polymeric matrices |
| 01/05/2006 | US20060002971 encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface; tissue engineering matrices, wound dressings, bone repair or regeneration materials |
| 01/05/2006 | US20060002966 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| 01/05/2006 | US20060002963 Use of emulsions for intra and periocular injections |
| 01/05/2006 | US20060002952 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 01/05/2006 | US20060002951 Inhibition of the tRNALys3-primed initiation of reverse transcription in HIV-1 by APOBEC3G |
| 01/05/2006 | US20060002950 Immunomodulatory protein derived from Trypanosomes and uses thereof |
| 01/05/2006 | US20060002940 Method of immunotherapy |
| 01/05/2006 | US20060002939 Monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal; light and heavy chains comprising complementarity determining regions |
| 01/05/2006 | US20060002938 Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| 01/05/2006 | US20060002937 Methods for treating conditions associated with MASP-2 dependent complement activation |
| 01/05/2006 | US20060002934 Egf receptor antagonists in the treatment of gastric cancer |
| 01/05/2006 | US20060002933 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| 01/05/2006 | US20060002926 isolated and/or recombinant; characterized by high affinity binding of one or more chemokines, such as eotaxin, RANTES and/or MCP-3, and/or the ability to stimulate a (one or more) cellular response(s) (e.g., chemotaxis, exocytosis, release of one or more inflammatory mediators) |
| 01/05/2006 | US20060002925 Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
| 01/05/2006 | US20060002919 15625 receptor, a novel G-protein coupled receptor |
| 01/05/2006 | US20060002918 Thrombin compositions |
| 01/05/2006 | US20060002917 Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo |
| 01/05/2006 | US20060002916 Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
| 01/05/2006 | US20060002915 Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| 01/05/2006 | US20060002914 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration |
| 01/05/2006 | US20060002913 Use of histamine and related compounds to treat disorders affecting muscle function |
| 01/05/2006 | US20060002912 Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| 01/05/2006 | US20060002911 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 01/05/2006 | US20060002901 Composition containing eosinophil cationic protein |
| 01/05/2006 | US20060002898 Methods and compositions for correction of cardiac conduction disturbances |
| 01/05/2006 | US20060002897 Plasmid for tissue targeted treatment of tumors; antitumor agents |
| 01/05/2006 | US20060002895 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 01/05/2006 | US20060002894 Method for introducing a biological molecule using a viral envelope and composition and system therefor |
| 01/05/2006 | US20060002892 Lectin-like transcript (LLTI); Natural killer cells; antitumor agents; quantitative analysis; human lectin transcription factor |
| 01/05/2006 | US20060002891 Cytomodulating conjugates of members of specific binding pairs |
| 01/05/2006 | US20060002874 Topical pharmaceutical composition to treat hyperpigmentation of the skin |
| 01/05/2006 | US20060002855 Targeted combination immunotherapy of cancer and infectious diseases |
| 01/05/2006 | US20060002854 Conjugate of therapeutic moiety linked to peptide having the amino acid sequence CGKRK, length < 400 residues, or a conservative variant or peptidomimetic; anticarcinogenic, -tumor agents; tissue-targeted therapy; side effect reduction; binds cognate receptor; angiogenesis inhibitors |
| 01/05/2006 | DE102004028899A1 Mittel zur Steigerung der Aktivität der sekretorischen Phospholipase A2-IIA Means for enhancing the activity of the secretory phospholipase A2-IIA |
| 01/05/2006 | DE102004028778A1 An oligopeptide, useful for controlling the biological activity of cellular biomolecules, comprising at least one cysteine residue and two alpha helical zones |
| 01/05/2006 | DE102004028156A1 Combination of radio waves and one or more of monoclonal antibodies, tyrosine-kinase inhibitors, angiogenesisi inhibitors, farnesyl transferase inhibitors, topoisomerase - I or II inhibitors, cytokine and antisense oligonucleotides |
| 01/05/2006 | DE102004027816A1 Verfahren zur Reinigung von Erythropoietin A process for the purification of erythropoietin |
| 01/05/2006 | DE102004026135A1 An MHC-Moleküle bindende Tumor-assoziierte Peptide Binding to MHC molecules tumor-associated peptides |
| 01/05/2006 | CA2612006A1 Phospholipid compositions and methods for their preparation and use |
| 01/05/2006 | CA2589563A1 Method of screening compound directly activating glycogen synthase |
| 01/05/2006 | CA2578592A1 Conjugates and therapeutic uses thereof |
| 01/05/2006 | CA2572330A1 Gdf3 propeptides and related methods |
| 01/05/2006 | CA2572193A1 Treatment of conditions involving oligodendrocytes with sp35 based agents |
| 01/05/2006 | CA2572015A1 Fc-interferon-beta fusion proteins |
| 01/05/2006 | CA2571852A1 Inhibition of infiltration, and cell killing agent |
| 01/05/2006 | CA2571781A1 Chimeric proteins and uses thereof |
| 01/05/2006 | CA2571444A1 Compositions for topical treatment |
| 01/05/2006 | CA2571420A1 Metastin derivatives and use thereof |